The results are in from drug giant Merck's most recent trial of a vaccine for Ebola — and they look pretty good:
The vaccine was 100 percent effective when it was tested on more than 4,000 people who were in close contact with Ebola patients in the African nation of Guinea, the World Health Organization said, citing a study published today in the Lancet medical journal. The trial of the vaccine, called Ebola ca suffit — "Ebola, that's enough" in French — began on March 23. [Bloomberg]
A panel overseeing the trial says a late-stage trial of the vaccine should proceed.
The Ebola outbreak that gripped West Africa last year — killing 11,000 people — has subsided, but the virus is stubbornly sticking around. New confirmed cases were reported this week.